Los puntos clave no están disponibles para este artículo en este momento.
Introduction: Alzheimer's disease, a progressive neurodegenerative condition, induces memory loss and cognitive impairments, posing significant challenges for patients, families, and caregivers. Cannabidiol (CBD), derived from cannabis, exhibits neuroprotective properties and influences cognition and behavior. Its therapeutic potential in Alzheimer's treatment is increasingly recognized, aiming to alleviate symptoms and improve patient outcomes. Objectives: This study aims to conduct an integrative review of cannabinoids' effects, particularly CBD, in treating Alzheimer's disease. Methods: An integrative literature review was conducted to explore the impact of cannabis-based treatments on Alzheimer's patients. Key health science databases such as LILACS, PubMed, Scopus, Web of Science, and Google Scholar were systematically searched using relevant descriptors (e.g., Cannabidiol, Tetrahydrocannabinol, Alzheimer's, Treatment). Results: Forty studies were identified from selected databases, with 37 meeting eligibility criteria for inclusion in this review. Discussion: CBD emerges as a complementary therapeutic option for managing neurological symptoms in Alzheimer's disease. Tetrahydrocannabinol (THC) demonstrates potential in altering patients' static balance and improving gait parameters. Other cannabinoids like cannabigerol (CBG) and cannabichromene (CBC) exhibit anti-inflammatory and anticonvulsant properties, respectively. However, further research is warranted to validate their efficacy in psychiatric disorders, including Alzheimer's disease. Conclusion: Phytocannabinoids exhibit promising neuroprotective effects in various neuropsychological conditions, including Alzheimer's disease. Although the use of cannabinoids shows tolerability among patients, rigorous studies are necessary to establish their true effectiveness and benefits in dementia management.
Bangash et al. (Thu,) studied this question.